Summit Therapeutics (SMMT) — AstraZeneca commits $2B strategic equity investment at <meta name="viewport" content="width=device-width, initial-scale=1.0" />8.36/sh (10% premium) after Mon Sept 28 close plus ivonescimab + sone-ve GI-cancer clinical collab; SMMT opens +22%, retraces to ~+6% Tues Sept 29

8.36/sh (10% premium) after Mon Sept 28 close plus ivonescimab + sone-ve GI-cancer clinical collab; SMMT opens +22%, retraces to ~+6% Tues Sept 29" /> 8.36/sh (10% premium) after Mon Sept 28 close plus ivonescimab + sone-ve GI-cancer clinical collab; SMMT opens +22%, retraces to ~+6% Tues Sept 29" />

Stock/TLDR — What Just Moved Markets: Earnings, Fed, M&A, MoversA high-volume feed of market-moving releases — quarterly earnings, FOMC decisions, M&A, regulatory actions, big single-name moves, macro prints, commodities and crypto — refreshed every 12 hours. Each release is explained in plain English so you actually understand what just happened and which tickers it touches.This site uses JavaScript to render the interactive feed. Enable JavaScript to use it.Stock/TLDR is not investment advice. Verify everything against primary sources before trading.